We studied the effect ofan arginine vasopressin (AVP) analogue, Evidence is also presented for competitive antagonism as the cellular mechanism of action.
Introduction
A specific antagonist of the antidiuretic action of arginine vasopressin (AVP)' has recently been synthesized by Manning et al. (1) . This AVP analogue, (l-[j-mercapto-3,f-cyclopentamethylenepropionic acid],2 -0 -ethyltyrosine,4 -valine)AVP (d-(CH2)5Tyr(Et)VAVP), inhibited the antidiuretic response to exogenous and endogenous AVP in the absence of changes in glomerular filtration rate, solute excretion, and blood pressure in the rat (2, 3) . In vitro studies in pig and human medullary membranes have also shown that the AVP analogue inhibits vasopressin binding (4, 5) . Since there is a 5:1 ratio of thick ascending Receivedfor publication S June 1985. limbs to collecting tubules in such medullary membrane preparations, a specific effect of the analogue on adenylate cyclase response of medullary collecting tubules (MCT) and papillary collecting tubules (PCT) cannot be ascertained from these studies.
The present study was undertaken to further characterize the cellular action ofthis AVP antagonist. Specifically, the effect of the AVP antagonist was examined on (a) 3H-AVP binding to rat papillary membranes, on (b) the activation of adenylate cyclase by AVP, parathyroid hormone (PTH), calcitonin, and glucagon in specific rat nephron segments, including collecting tubule and thick ascending limb segments, and on (c) water flux across isolated perfused rabbit cortical collecting tubules (CCT). Taken together, the results ofthese in vitro experiments indicate that the AVP analogue is a specific inhibitor ofthe cellular action of AVP in the medullary thick ascending limb, CCT, MCT, and PCT of the rat. A specific inhibition of AVP-induced water flux across the isolated perfused CCT of the rabbit was also demonstrated. Evidence is presented in support of competitive antagonism as the cellular mechanism of action.
Methods
Microdissection oftubules. Male Sprague-Dawley rats (200-250 g body weight) were lightly anesthetized with pentobarbital (3 mg/100 g body weight) and the left kidney was perfused with 10 ml of collagenase medium (137 mM NaCl, 5 mM KCI, 0.8 mM MgSO4, 0.8 mM Na2HPO4, 1 mM MgCI2, 0.25 mM CaC12, 10 mM Tris, pH 7.4, 10-20 U/ml collagenase [Millipore Corp., Greenhold, NJ], 1 mg/ml hyaluronidase [Sigma Chemical Co., St. Louis, MO], and 1 mg/ml bovine serum albumin with 20 U/ml heparin) at an infusion rate of I ml/min. The cortical, medullary, and papillary tissue was dissected and sliced to thin strips with direction from cortex to papillary tip. Then the pieces were incubated in an aerated collagenase medium for 60 min for papillary tissue and 30 min for cortical and medullary tissues at 35°C. After incubation the tissues were washed with cold microdissection medium (same as the collagenase medium, except with I mM CaCl2 and no collagenase, hyaluronidase, or bovine serum albumin) and kept on ice while microdissection was performed. CCT, MCT, and PCT, as well as the thick ascending limb of Henle's loop from cortex (CAL) and medulla (MAL), were dissected under a stereomicroscope using thin needles. Dissected tubules were transferred to a concave bacteriological slide by aspiration of tubules in a small droplet of microdissection medium. The tubules were then photographed to measure the lengths. The tubules were disrupted by hypoosmotic shock and freezing. After the microdissection, medium was aspirated off, 0.5
Ml hypoosmotic medium (I mM MgCl2, 0.25 mM EDTA, 0.1% bovine serum albumin, and 1 mM Tris, pH 7.4) was added under the microscope; the samples were then frozen immediately by placing them on a block of dry ice. The frozen tubules were thawed once and refrozen, then kept at -80°C until assayed. The basal and hormone-stimulated activities of adenylate cyclase were stable at least for 5 d at -80°C.
Assays ofadenylate cyclase and cAMP-phosphodiesterase activity on tubules. The activity of adenylate cyclase was measured according to a modification (6) of the method of Morel et al. (7) . Slides ( 12) . The reaction medium contained 0.25 mM creatine phosphate, 0.1 mg/ml creatine phosphokinase, 2.5% bovine serum albumin, 4 mM MgCl2, 0.1 mM EDTA, 0.5 mM cAMP, and 40 mM Tris buffer, pH 7.4.
Approximately 100 Mg of protein was used and the final volume was 100 Ml. The reaction was started by addition of 3H-AVP with appropriate concentration, and incubated at 30°C for 15 min. At the end of the incubation the tubes were placed in ice and vortexed, and immediately two 40-Ml samples of the mixture were carefully layered over cold 300
Ml of stopping solution (2.5% bovine serum albumin, 100 mM Tris-HCl, pH 7.4) in the Eppendorf microcentrifuge tube (Brinkman Instruments, Inc., Palo Alto, CA) at 2°C to 4°C. After centrifugation, the supernatant solution was aspirated off under a bright illuminator. The pellet was carefully washed with cold 300 Ml ofwashing solution (10% sucrose, 100 mM Tris, pH 7.4) without disturbing the pellet. After aspiration of the washing solution, the tip of the microtube was cut at a point just above the pellet. The tip with pellet was transferred into a counting vial containing scintillation cocktail (Insta-gel [Packard Instrument Co., Inc., Downer's Grove, IL]) and counted in a Packard Tri-Carb 460C liquid scintillation counter. The nonspecific binding of 3H-AVP was determined in the presence of 10-5 M AVP. The nonspecific binding at each concentration of 3H-AVP was not constant. As 3H-AVP increased the nonspecific binding was increased gradually also. For example, at 5 X 10-9 M 3H-AVP the nonspecific binding was 8.8%; at I X i0-0 M, 15.6%; at 2.5 X 10-8M, 21 (14, 15) . New Zealand white rabbits weighing 1-2 kg were maintained on rabbit chow (Purina, St. Louis, MO) and ad libitum water. The animals were killed by cervical dislocation and the left kidney was removed quickly. 1-2-mm slices were cut along the cortico-medullary axis and placed in a glass dish in a solution of 115 mM NaCi, 1.2 mM MgSO4, 1.0 mM CaC12, 5.0 mM KCl, 10 mM sodium acetate, 1.2 mM NaH2PO4, 25 mM NaHCO3, and 5.5 mM dextrose with 5% bovine serum albumin. This solution was maintained at 4VC and pH of 7.4 during dissection. The cortex was separated from outer medulla and CCT were dissected from medullary rays. Collecting tubules were identified by the presence of branching, straight configuration, light granular appearance with fuzzy borders, and generally open lumens. Tubules were taken distal to the last branch. Tubules were transferred to a lucite perfusion chamber (volume -2.0 ml) set on the stage ofan inverted phase-contrast microscope (Olympus, Model CK, Tokyo, Japan).
Custom capillary glass (Drummond Scientific Co., Broomall, PA) was used to fashion (Stoelting Microforge, Chicago, IL) pipettes of required dimensions. Tubules were aspirated into the tip ofa holding pipette (outer diameter -32-36 Mm) up to a constriction of 16-18 Mm. A perfusion pipette (-12-14 Mm) was advanced into the lumen and extended 50-100 Mm beyond the tip of the holding pipette. A large outer pipette containing Sylgard 184 (Dow Coming Corp., Midland, MI) was advanced over the tip of the holding pipette so that Sylgard covered the holding pipette and tubule up to the tip of the perfusion pipette. A fluid exchange pipette inside the perfusion pipette was used to change perfusate composition. The free end of the tubule was aspirated into a collection pipette, which had an inner diameter slightly less than the outer diameter of the tubule. The tip of the pipette was filled with Sylgard 184 and the tubule was aspirated through the Sylgard. Water equilibrated mineral oil was introduced into the collection pipette and a calibrated volumetric pipette (80-1 10 ni) was used to obtain precisely timed samples ofconstant volume. Samples were separated by mineral oil.
Tubules were bathed in the same solution used for dissection, except that no albumin was present. Bath fluid of pH 7.4 and temperature of 250C (16) was completely changed every 5 min. All studies were carried out at 250C because the hydroosmotic response to vasopressin appears to be stable at this temperature (16) . Tubules were perfused at rates of 5-15 nl/min by adjusting hydrostatic pressure of the fluid entering the fluid exchange pipette. Perfusion fluid composition was the same as bathing fluid, except that the final concentration of NaCi was reduced to 50 mM. This resulted in an approximate 100-mOsm gradient from lumen to bathing fluid. Perfusion fluid contained a sufficient amount of '4C-inulin (New England Nuclear, Boston, MA) to result in collected fluid counts per minute 10-fold above background The [C14] inulin was dissolved in perfusion solution a few minutes before use. Tubules were perfused for 150-180 min before studies were begun. The tubule was visually inspected throughout the duration of the study. Tubular length was measured at the conclusion ofeach study by a calibrated microscope eyepiece reticle.
Collected samples were placed under water equilibrated mineral oil in the bottom of a siliconized dish. 50-nl aliquots of these samples were taken for scintillation counting (Packard Tricarb 460C Another set of experiments were performed using each tubule as its own control to test the effect of AVP analogue on the AVP-stimulated Lp. In these experiments'AVP analogie (2.5 X 10-' M) was introduced into the bath for I h. AVP (250 MU/ml) was then added to the bath. Salmon calcitonin (SCT), in both maximal (3 X I0-' M) or submaximal stimulatory concentration (1.5 X 10-8 M), significantly increased the adenylate cyclase in CCT, and 10-6 M d(CH2)5Tyr(Et)VAVP did not affect the stimulation of adenylate cyclase by SCT (Table II) .
MAL. The adenylate cyclase in MAL from the rats that were used for studies of collecting tubules (Charles River SpragueDawley, Wilmington, MA) did not respond to AVP. A different strain of Sprague-Dawley rats (Harlan Rats, Indianapolis, IN) were used in the study of MAL. The adenylate cyclase response to AVP in the collecting tubules was the same in the Charles River and Harlan rats (17) .
AVP (10-6 M) significantly stimulated adenylate cyclase as shown in Table I Studies of3H-A VP binding to renal papillary plasma membranes. 3H-AVP binding to the renal papillary membranes was studied in the absence and presence of 10-9, l0-7, and 10-6 M AVP analogue. 3H-AVP binding to the renal papillary membranes was dose-dependent when the specific 3H-AVP binding was plotted as a function of the 3H-AVP concentration in the incubation medium (Fig. 2) . 10 the AVP analogue was removed from the bath (mean 79±41 Study of net water flux across the isolated perfused rabbit x 10-7 cm/s. atm). As can be seen AVP analogue significantly CCT. The effect of AVP on hydraulic conductivity in the pres-inhibited the effects ofAVP until the AVP analogue was removed ence and absence of the analogue is depicted in Fig. 3 . from the bath (P < 0.05). analogue. In contrast, no significant increase in Lp was observed human medullopapillary membranes (4, 5 ceptor sites of AVP action on the MAL or MCT. In these studies, the dissociation constant in the renal papillary membrane (1.4 X 10-8 M) was similar to that observed in human medullopapillary membranes (1.6 X IO-' M) (5). The apparent inhibition constants (K*) of d(CH2)5Tyr(Et)VAVP in rat papillary membranes (9 X 10-' M) was also similar to that observed in medullopapillary membranes of human (5.9 X 10-9 M) (5).
The earlier results using renal medullopapillary membranes (4, 5) were compatible with a competitive antagonism as the cellular action of d(CH2)5Tyr(Et)VAVP. In the present study (Fig. 2) be used because of too high and irregular nonspecific binding. The dose response curve of adenylate cyclase response to AVP in the papillary collecting tubule in the presence ofAVP analogue showed the same pattern as 3 I-AVP. Specifically, AVP (10-6 M) was shown to overcome the antagonist's effect (10-9 M) to inhibit the stimulation of adenylate cyclase in the rat renal papillary collect duct. Taken together, these results support competitive antagonism as the cellular mechanism of action of the antagonist.
To identify the specific nephron sites of action of the AVP analogue, we investigated its effect on activation of adenylate cyclase by AVP in various segments of the nephron. The AVP analogue was shown to diminish the activation of adenylate cyclase in the PCT in a dose-response manner. Since AVP is known also to act in the MCT and CCT, studies were performed in these dissected segments of the rat nephron. In these studies the AVP analogue also blocked the effect of AVP to stimulate adenylate cyclase. Since the adenylate cyclase is more sensitive in the PCT than MCT and CCT (unpublished observations), different concentrations of AVP and the AVP analogue were used in the separate segments. Since AVP has been shown to activate adenylate cyclase in the MAL in some species, including the rat (6, (19) (20) (21) (22) (23) (24) (25) , the effect of the analogue in this nephron segment was also examined. The stimulation ofadenylate cyclase by AVP in MAL, MCT, and CCT were also inhibited by this analogue, indicating that this AVP analogue has effects on the same nephron sites where AVP acts.
The in vitro specificity of the analogue for AVP was further examined in a group of studies using submaximal and maximal stimulatory concentrations of several hormones known to stimulate adenylate cyclase in various segments of the rat nephron. These results confirmed the specificity of the AVP analogue for AVP sites of action in nephron. Specifically, the AVP analogue did not alter the stimulation of adenylate cyclase by PTH in the CAL, by calcitonin in the CCI, or by glucagon in the MAL.
These in vitro studies were compatible, therefore, with the in vivo observations (2, 3) (3) . Further evidence for a direct cellular effect was obtained by examining the in vitro antagonism by the analogue on AVP-induced water flux in the isolated CCT. The results demonstrated that the effect of AVP to increase hydraulic conductivity and to enhance osmotic water flux across the isolated perfused cortical tubule of the rabbit was abolished by the AVP analogue. The early (10-min) transient agonistic effect of the AVP analogue seen in the hydraulic conductivity of CCT was also observed in the in vivo study (3) . This transient agonistic effect of the AVP analogue was not demonstrable on the adenylate cyclase response of collecting tubules, since the in vitro enzyme assay was conducted after a 30-min, fixed reaction time period.
Thus, the present in vitro studies demonstrated effects ofthe AVP analogue to (a) diminish AVP binding in rat papillary membranes, (b) decrease adenylate cyclase activation in the rat MAL as well as the CCT, MCT, and PCT, (c) not alter the specific effects of PTH, calcitonin, and glucagon on adenylate cyclase activation in specific rat nephron segments, and (d) to block the effect of AVP to increase hydraulic conductivity and water flux on isolated perfused CCT of the rabbit. Evidence is presented for competitive antagonism as the cellular mechanism of action. This analogue has also been recently shown in vivo to reverse the water retention associated with either glucocorticoid or mineralocorticoid deficiency in the adrenally insufficient conscious rat (26) . There is, thus, potential clinical and experimental use for this exciting new AVP analogue.
